Literature DB >> 23851103

Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum".

Philip D H Hamann1, Robert G Cooper, Neil J McHugh, Hector Chinoy.   

Abstract

Statin-induced necrotizing myositis is increasingly being recognised as part of the "statin-induced myopathy spectrum". As in other immune-mediated necrotizing myopathies, statin-induced myositis is characterised by proximal muscle weakness with marked serum creatinine kinase elevations and histological evidence of myonecrosis, with little or no inflammatory cell infiltration. Unlike other necrotizing myopathies, statin-induced myopathy is associated with the presence of autoantibodies directed against 3-hydroxy-3-methylglutaryl- coenzyme A reductase (the enzyme target of statin therapies), and with Human Leukocyte Antigen-DRB1*11. This article summarises the clinical presentation, investigations and management of this rare, but serious complication of statin therapy.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  200/100kDa; Antibody; HMGCR; Myositis; Necrotizing; Statin

Mesh:

Substances:

Year:  2013        PMID: 23851103      PMCID: PMC4589155          DOI: 10.1016/j.autrev.2013.07.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  32 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

3.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

4.  Antibody to signal recognition particle in polymyositis.

Authors:  I N Targoff; A E Johnson; F W Miller
Journal:  Arthritis Rheum       Date:  1990-09

5.  Skeletal muscle necrosis associated with cainoma.

Authors:  B Smith
Journal:  J Pathol       Date:  1969-02       Impact factor: 7.996

6.  Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Authors:  Jessie L Werner; Lisa Christopher-Stine; Sharon R Ghazarian; Katherine S Pak; Jordan E Kus; Natalie R Daya; Thomas E Lloyd; Andrew L Mammen
Journal:  Arthritis Rheum       Date:  2012-12

Review 7.  Myositis or dystrophy? Traps and pitfalls.

Authors:  Olivier Benveniste; Norma B Romero
Journal:  Presse Med       Date:  2011-03-04       Impact factor: 1.228

8.  Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.

Authors:  Andrew L Mammen; Katherine Pak; Emma K Williams; Diane Brisson; Joe Coresh; Elizabeth Selvin; Daniel Gaudet
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-02       Impact factor: 4.794

Review 9.  Toxic and drug-induced myopathies.

Authors:  M C Dalakas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-08       Impact factor: 10.154

10.  Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).

Authors:  Pernette R W de Sauvage Nolting; Rudolf J A Buirma; Barbara A Hutten; John J P Kastelein
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

View more
  27 in total

1.  Acute myonecrosis on MRI: etiologies in an oncological cohort and assessment of interobserver variability.

Authors:  Jane Cunningham; Richa Sharma; Anna Kirzner; Sinchun Hwang; Robert Lefkowitz; Daniel Greenspan; Anton Shapoval; David M Panicek
Journal:  Skeletal Radiol       Date:  2016-04-22       Impact factor: 2.199

2.  Statin-induced necrotizing autoimmune myopathy.

Authors:  Syed A Huda; Sanjay Yadava; Sara Kahlown; Muhammad S Farooqi; Stephanie Bryant; Ronald Russo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-10-21

Review 3.  Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms-A Good Idea, but….

Authors:  Amanda L Zaleski; Beth A Taylor; Paul D Thompson
Journal:  Adv Nutr       Date:  2018-07-01       Impact factor: 8.701

Review 4.  A case of statin-associated immune-mediated necrotizing myopathy with atypical biopsy features.

Authors:  Mark M Zaki; Zain M Virk; Diego Lopez; Jenna Klubnick; Jared T Ahrendsen; Hemant Varma; Vasileios Kyttaris; Ilana Abeles
Journal:  Eur J Rheumatol       Date:  2021-01-01

5.  Complement membrane attack complex is related with immune-mediated necrotizing myopathy.

Authors:  Lu Cong; Chuan-Qiang Pu; Qiang Shi; Qian Wang; Xiang-Hui Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  Dead Meat: Glecaprevir/Pibrentasvir-Induced Statin Myonecrosis.

Authors:  Katherine Wong; Alexander Podboy; Jonathan Lavezo; Aparna Goel
Journal:  Dig Dis Sci       Date:  2020-02       Impact factor: 3.199

7.  Atypical presentation of necrotising autoimmune myopathy.

Authors:  Oyintayo Ajiboye; Michelle Manesh; Nisar Asmi; Benjamin Mba
Journal:  BMJ Case Rep       Date:  2019-05-28

Review 8.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 9.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

Review 10.  Selected aspects of the current management of myositis.

Authors:  James Lilleker; Sean Murphy; Robert Cooper
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-06-19       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.